GlassScriptPhysician profile
Gurdip S Flora
NPI 1164611075
$1,885.86
in general payments reported to CMS, 2019-2025
25 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $234 · 2021: $232 · 2022: $475 · 2023: $313 · 2024: $338 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $447.35 | 2019-2022 | |
| Philips North America LLC | $180.30 | 2022-2024 | (8874) Incourage |
| Abbvie INC. | $178.28 | 2022-2025 | |
| Mylan Specialty L.P. | $165.73 | 2021-2024 | Yupelri |
| Abbott Laboratories | $111.47 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Lundbeck LLC | $106.12 | 2020-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $91.76 | 2022-2023 | |
| Glaxosmithkline, LLC. | $82.32 | 2020-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $64.63 | 2023-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $63.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.06 | 2020-2022 | |
| Viatris Specialty LLC | $57.95 | 2025 | Yupelri |
| Pfizer INC. | $42.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.98 | 2019-2020 | |
| Ardelyx, INC. | $29.17 | 2024 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.84 | 2024 | |
| Neurocrine Biosciences, INC. | $21.82 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2022 | |
| Electromed, INC. | $17.82 | 2022 | |
| Allergan, INC. | $15.50 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $14.12 | 2025 | |
| Daiichi Sankyo INC. | $13.85 | 2022 | |
| Urovant Sciences INC | $13.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.20 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurdip Flora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.